Plecanatide is a synthetic, orally administered medication primarily used for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation. It is classified as a guanylate cyclase-C (GC-C) agonist, which means it activates the GC-C receptor in the intestinal lining, leading to increased levels of cyclic guanosine monophosphate (cGMP). This action promotes fluid secretion in the intestines and enhances gastrointestinal motility. Plecanatide is characterized by its peptide-like structure, which contributes to its mechanism of action and pharmacokinetics. It is generally well-tolerated, with common side effects including diarrhea and abdominal discomfort. The substance is designed to mimic the natural hormone uroguanylin, which plays a role in regulating intestinal fluid balance. As a prescription medication, plecanatide is subject to regulatory oversight and is typically prescribed when other treatments for constipation have proven ineffective. Its efficacy and safety profile have been established through clinical trials, making it a valuable option in the management of specific gastrointestinal disorders.

Plecanatide

467426-54-6: Plecanatide is a synthetic, orally administered medication primarily used for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation. It is classified as a guanylate cyclase-C (GC-C) agonist, which means it activates the GC-C receptor in the intestinal lining, leading to increased levels of cyclic guanosine monophosphate (cGMP). This action promotes fluid secretion in the intestines and enhances gastrointestinal motility. Plecanatide is characterized by its peptide-like structure, which contributes to its mechanism of action and pharmacokinetics. It is generally well-tolerated, with common side effects including diarrhea and abdominal discomfort. The substance is designed to mimic the natural hormone uroguanylin, which plays a role in regulating intestinal fluid balance. As a prescription medication, plecanatide is subject to regulatory oversight and is typically prescribed when other treatments for constipation have proven ineffective. Its efficacy and safety profile have been established through clinical trials, making it a valuable option in the management of specific gastrointestinal disorders.

Plecanatide acetate is an analogue of Uroguanylin. It is an orally active guanylate cyclase-C (GC-C) receptor agonist.

CAS 467426-54-6

Plecanatide

Plecanatide

Ref: IN-DA01EFHY

Plecanatide

Ref: TM-T9080